http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Optical anisotropy in single-walled carbon nanotubes.
Yoo, Seongwoo,Jung, Yongmin,Lee, Dong Soo,Han, Won-Taek,Oh, Kyunghwan,Murakami, Y,Edamura, T,Maruyama, Shigeo Optical Society of America 2005 Optics letters Vol.30 No.23
<P>Optical anistropy at optical communication wavelength was observed in films of vertically aligned single-walled carbon nanotubes (SWNTs). We report the control of both the polarization state and transmission of incoming light at 1550 nm by azimuthal and axial tilting of SWNT film about its aligned axis. The experiments reveal that the polarization state of light is susceptible to the azimuthal angle of the aligned direction of a SWNT having semiconductor characteristics and the intensity of the output beam after SWNT film shows cosine function dependence on the axial tilting angle.</P>
The Third Nationwide Korean Heart Failure III Registry (KorHF III): The Study Design Paper
Yoon Minjae,Kim Eung Ju,Han Seongwoo,Park Seong-Mi,Kim In Cheol,Cho Myeong-Chan,안효석,신미승,Hwang Seokjae,Jeong Jin-Ok,Yang Dong Heon,Kim Jae-Joong,최진오,Cho Hyun-Jai,Yoo Byung-Su,Kang Seok Min,Choi Dong-Ju 대한심부전학회 2024 International Journal of Heart Failure Vol.6 No.2
With advancements in both pharmacologic and non-pharmacologic treatments, significant changes have occurred in heart failure (HF) management. The previous Korean HF registries, namely the Korea Heart Failure Registry (KorHF-registry) and Korean Acute Heart Failure Registry (KorAHF-registry), no longer accurately reflect contemporary acute heart failure (AHF) patients. Our objective is to assess contemporary AHF patients through a nationwide registry encompassing various aspects, such as clinical characteristics, management approaches, hospital course, and long-term outcomes of individuals hospitalized for AHF in Korea. This prospective observational multicenter cohort study (KorHF III) is organized by the Korean Society of Heart Failure. We aim to prospectively enroll 7,000 or more patients hospitalized for AHF at 47 tertiary hospitals in Korea starting from March 2018. Eligible patients exhibit signs and symptoms of HF and demonstrate either lung congestion or objective evidence of structural or functional cardiac abnormalities in echocardiography, or isolated right-sided HF. Patients will be followed up for up to 5 years after enrollment in the registry to evaluate long-term clinical outcomes. KorHF III represents the nationwide AHF registry that will elucidate the clinical characteristics, management strategies, and outcomes of contemporary AHF patients in Korea. Trial Registration ClinicalTrials.gov Identifier: NCT04329234 With advancements in both pharmacologic and non-pharmacologic treatments, significant changes have occurred in heart failure (HF) management. The previous Korean HF registries, namely the Korea Heart Failure Registry (KorHF-registry) and Korean Acute Heart Failure Registry (KorAHF-registry), no longer accurately reflect contemporary acute heart failure (AHF) patients. Our objective is to assess contemporary AHF patients through a nationwide registry encompassing various aspects, such as clinical characteristics, management approaches, hospital course, and long-term outcomes of individuals hospitalized for AHF in Korea. This prospective observational multicenter cohort study (KorHF III) is organized by the Korean Society of Heart Failure. We aim to prospectively enroll 7,000 or more patients hospitalized for AHF at 47 tertiary hospitals in Korea starting from March 2018. Eligible patients exhibit signs and symptoms of HF and demonstrate either lung congestion or objective evidence of structural or functional cardiac abnormalities in echocardiography, or isolated right-sided HF. Patients will be followed up for up to 5 years after enrollment in the registry to evaluate long-term clinical outcomes. KorHF III represents the nationwide AHF registry that will elucidate the clinical characteristics, management strategies, and outcomes of contemporary AHF patients in Korea. Trial Registration ClinicalTrials.gov Identifier: NCT04329234
The Prognostic Implication of Metabolic Syndrome in Patients with Heart Failure
윤현주,안영근,김계훈,박종춘,최동주,Seongwoo Han,전은석,조명찬,Jae-Joong Kim,Byung-Su Yoo,신미승,성인환,Seok-Min Kang,Yung-Jo Kim,Hyung Seop Kim,채성철,오병희,Myung-Mook Lee,유규형 대한심장학회 2013 Korean Circulation Journal Vol.43 No.2
Background and Objectives: Metabolic syndrome (MetS) increases the risk of heart failure (HF). The purpose of this study was to identi-fy the prevalence of MetS in patients with HF and determine the syndrome’s association with HF in clinical and laboratory parameters. Subjects and Methods: A total of 3200 HF patients (67.6±14.5 years) enrolled in a nationwide prospective Korea HF Registry between Jan. 2005 and Oct. 2009. Patients were divided into two groups according to the presence or absence of MetS at admission: group I (pres-ence, n=1141) and group II (absence, n=2059). Results: The prevalence of MetS was 35.7% across all subjects and was higher in females (56.0%). The levels of white blood cells, platelets,creatinine, glucose, and cholesterol were significantly higher in group I than in group II. Left ventricular dimension and volume was smaller and ejection fraction was higher in group I than in group II. An ischemic cause of HF was more frequent in group I. The rates of valvular and idiopathic cause were lower in group I than in group II. The rate of mortality was lower in group I than in group II (4.9% vs. 8.3%, p<0.001). Conclusion: Despite the increased cardiovascular risks in MetS, MetS was found to be associated with decreased mortality in HF.
Rapid exacerbation of renal function after administration of hydroxyethyl starch in a dog
BAE, Junwoo,SOLIMAN, Mahmoud,KIM, Hyunwoo,KANG, Seongwoo,KIM, Woosun,AHN, Soomin,CHO, Kyoungoh,CHOI, Jihye,KIM, Suhee,PARK, Jinho,KIM, Sangki,DO, Yoonjung,YOO, Jaegyu,YU, Dohyeon JAPANESE SOCIETY OF VETERINARY SCIENCE 2017 The Journal of veterinary medical science Vol.79 No.9
<P>Hydroxyethyl starches (HES) are commonly used synthetic colloidal solution in veterinary medicine. Despite of possible adverse effect to kidney injury in human, there is no report about nephrotoxic effects of HES in dogs. HES was administered to a Golden retriever (4-year-old, intact male) with ascites in order to increase plasma osmolality. Initially, the dog was mild azotemic, however, kidney function was rapidly deteriorated after several days of HES administration. Finally, histopathological examination revealed remarkable osmotic nephrosis. In the case reported herein, acute kidney injury was remarkably developed after HES administration. Clinical and histopathologic findings of acute kidney injury support nephrotoxic effects of HES to a dog.</P>